Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
ICON to conduct U.S. government trial of next-gen COVID-19 vaccines
This news article, published on FIERCE Biotech, highlights that ICON is partnering with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial to evaluate next-generation vaccines for COVID-19.
-
Disease surveillance and vaccine development
In this article in Life Science Review, Dinah Knotts, Vice President, project management, Vaccines and Infectious Disease, ICON plc outlines how disease surveillance can play an important role in emerging infectious disease early.
-
Developing mRNA vaccine technology
In this article, Dinah Knotts, Vice President of Project Management at ICON, speaks about mRNA vaccine technology and what further opportunities it can offer in fighting infectious diseases.
-
The contribution of companies during the Covid-19 pandemic
Rose Kidd, President, Operations Delivery outlines the role ICON played in the search for vaccines and treatments for Covid-19 in the American Chamber of Commerce Ireland 2023 US-Ireland Business Report.
2023 American Chamber of Commerce Ireland
-
Fortifying vaccines through disease surveillance and data reporting
In this article, McLendon explores the topic of fortifying vaccines against future pandemics.
-
Measuring the cost-effectiveness of vaccines targeting infectious diseases
ICON's Richard Pitman and Pragya Khurana provide insights on the use of real world evidence to build cost-effectiveness models that demonstrate the value that vaccines bring to healthcare systems.
-
Responsive strategies in vaccine development
Shelley McLendon discusses the importance of disease surveillance, developments in early outbreak detection, and the role of smart data reporting and adaptive trial designs.
-
Anthrax vaccine clinical trial
This news article, first published on Contract Pharma.com, outlines how ICON has been selected by BARDA to execute an anthrax vaccine clinical trial.
-
Continuing the fight against antimicrobial resistance
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, offers her insights on the necessary actions to combat the threat of AMR.
This article is taken from European Biopharmaceutical Review April 2022, pages 8-10. Samedan Ltd.
-
Irish businesses back global vaccine drive
This article summarises the companies, including ICON, who are backing UNICEF’s drive to supply 2 billion vaccines to the developing world.
